Abstract

Nicotinic acetylcholine receptors (nAChR) are ligand gated ion channels, identified as therapeutic targets for a range of human diseases. Drug design for nAChR related disorders is increasingly using structure-based approaches. Many of these structural insights for therapeutic lead development have been obtained from co-crystal structures of nAChR agonists and antagonists with the acetylcholine binding protein (AChBP). AChBP is a water soluble, structural and functional homolog of the extracellular, ligand-binding domain of nAChRs. Currently, AChBPs are recombinantly expressed in eukaryotic expression systems for structural and biophysical studies. Here, we report the establishment of an Escherichia coli (E. coli) expression system that significantly reduces the cost and time of production compared to the existing expression systems. E. coli can efficiently express unglycosylated AChBP for crystallography and makes the expression of isotopically labelled forms feasible for NMR. We used a pHUE vector containing an N-terminal His-tagged ubiquitin fusion protein to facilitate AChBP expression in the soluble fractions, and thus avoid the need to recover protein from inclusion bodies. The purified protein yield obtained from the E. coli expression system is comparable to that obtained from existing AChBP expression systems. E. coli expressed AChBP bound nAChR agonists and antagonists with affinities matching those previously reported. Thus, the E. coli expression system significantly simplifies the expression and purification of functional AChBP for structural and biophysical studies.

Highlights

  • Nicotinic acetylcholine receptors are promising drug targets for a range of human neurodegenerative diseases [1,2,3,4,5,6]

  • acetylcholine binding protein (AChBP) and Deubiquitinylating enzyme (DUB) expression levels were evaluated at different temperatures and induction methods to determine the optimum parameters for protein expression (Table 3)

  • Lymnaea stagnalis (Ls)-AChBP expressed at lower temperature (16°C) was more stable during purification, routine expression of Ls-AChBP was performed at 16°C

Read more

Summary

Introduction

Nicotinic acetylcholine receptors (nAChR) are promising drug targets for a range of human neurodegenerative diseases [1,2,3,4,5,6]. E. coli Expression of AChBPs crystallography [9, 12,13,14,15] This challenge has been side-stepped to a significant extent by the use of acetylcholine binding protein (AChBP) as the soluble structural and functional homolog of the nAChR ligand binding domain [13, 16,17,18]. AChBPs have enabled the application of crystallography and solution based techniques to obtain high resolution insights into nAChRligand interactions, required for efficient drug lead optimizations [9, 12, 19, 20]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call